---
title: "Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Antiseizure medications"
description: "Formulary evidence on Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Antiseizure medications. Topics: Consensus guideline: neurology referral and antiseizure medication monitoring, Natural History Study: remission and medication withdrawal, Antiseizure drug selection: comparative evidence and adverse-effect considerations, Review: lack of comparative studies and non-pharmacological options for refractory epilepsy, and 6 further topics. 10 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description/antiseizure-medications"
published: "2026-11-15T20:23:41-05:00"
modified: "2026-11-15T20:23:41-05:00"
---

# Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Antiseizure medications

<a id="heading-2.2.2.1.2"></a>

## 2.2.2.1.2 Antiseizure Medications

<a id="topic-2.2.2.1.2-1"></a>

### Consensus guideline: neurology referral and antiseizure medication monitoring

> “Refer to neurologist for seizures and spells suspicious for seizures, with follow-up every 6 months if treated with an anticonvulsant. It is difficult to differentiate between a non-epileptic Rett spell and a seizure (both may be present).”
> “If the individual’s weight fluctuates (more than 10%–20%), request the neurologist to consider adjusting anticonvulsant doses accordingly. Laboratory follow-up as needed for use of antiseizure medications.”
> “but there have been no randomised controlled trials of specific anticonvulsants for RTT.”

Source: [Fu et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7488790/)

<a id="topic-2.2.2.1.2-2"></a>

### Natural History Study: remission and medication withdrawal

> “Although 248 of those with classic Rett syndrome and a history of seizures were in terminal remission at last contact, only 74 (12% of those with a history of epilepsy) were seizure free and off anti-seizure medication.”
> “Notably, persistent drug resistant epilepsy without remission is not the most common pattern, only affecting 16% of those with classic Rett syndrome, a figure less than half that of the Italian and Australian studies.”

Source: [Tarquinio et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5278305/)

<a id="topic-2.2.2.1.2-3"></a>

### Antiseizure drug selection: comparative evidence and adverse-effect considerations

> “Although cases and retrospective studies document efficacy of specific medications in Rett syndrome, no systematic study has demonstrated superiority of a specific medication or class of medications to treat epilepsy in Rett syndrome”
> “No specific medications are contraindicated in Rett syndrome; however, the issue of bone health is an important consideration when prescribing anti-seizure drugs.”
> “In summary, when seizures are concluded to be epileptic in origin and anti-seizure drugs are initiated, the side effect profiles of medications should be considered carefully, and medications, which can cause behavioural issues (e.g. levetiracetam), anorexia and nephrolithiasis (e.g. topiramate), QT interval prolongation (e.g. felbamate), or marked sedation (e.g. benzodiazepines), should be used with caution.”

Source: [Tarquinio et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5278305/)

<a id="topic-2.2.2.1.2-4"></a>

### Review: lack of comparative studies and non-pharmacological options for refractory epilepsy

> “There are problems in evaluating the treatment efficiency of AED due to the general lack of comparative studies and the number of different AED used in monotherapy or combination treatment in RTT.”
> “Due to limited experience of epilepsy treatment in RTT, no definite recommendation regarding anticonvulsants is currently available.”
> “The ketogenic diet and vagal nerve stimulation have been reported to be effective treatment options in some refractory RTT cases.”

Source: [Krajnc (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4468994/)

<a id="topic-2.2.2.1.2-5"></a>

### Antiseizure medications prescribed in a US electronic health record cohort

| Antiseizure medication | Participants with epilepsy, n (%) (N = 59) |
| --- | --- |
| Levetiracetam | “27 (45.8%)” |
| Clonazepam | “22 (37.3%)” |
| Oxcarbazepine | “18 (30.5%)” |
| Lamotrigine | “15 (25.4%)” |
| Valproate or valproic acid | “15 (25.4%)” |
| Topiramate | “10 (16.9%)” |
| Lacosamide | “7 (11.9%)” |

Source: [Rashid et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12549289/)

<a id="topic-2.2.2.1.2-6"></a>

### Drug-resistant epilepsy and absence of first-line recommendations

> “While AEDs are effective therapy, either as monotherapy or in combination, for many individuals who have seizures in RTT, 20–40% experience drug-resistant epilepsy”
> “Due to the non-localized nature of epilepsy in RTT, unlike individuals with other types epilepsy (i.e., focal onset epilepsy), surgical treatments are generally not effective for drug-resistant epilepsy in RTT”

Source: [Rashid et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12549289/)

<a id="topic-2.2.2.1.2-7"></a>

### Cannabidiol for drug-resistant epilepsy: Italian multicenter cohort

> “We enrolled 27 subjects (26 females), carrying a MECP2 genetic variant (14 subjects, 51.9%) or a CDKL5 genetic variant (13 subjects, 48.1%).”
> “Although not reaching a significant statistical effect, CBD reduced the incidence of seizures with respect to the baseline in 18/27 (66.6%) subjects, with 7 (25.9%) showing a seizure reduction >75%, and 11 (40.7%) >50%.”
> “The most relevant adverse events were somnolence seen in 3 subjects, irritability/agitation in 2 subjects, loss of appetite in 2 subjects, and insomnia in 1 individual.”

Source: [Vignoli et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12362169/)

<a id="topic-2.2.2.1.2-8"></a>

### Cannabidiol as adjunctive therapy: French single-center cohort

> “In our cohort, 26 patients had associated epilepsy (26/46 [56%]), and 10/26 (38%) were treated with CBD, in combination with clobazam in 50% of cases.”
> “CBD reduced the incidence of seizures in seven out of 10 patients (70%) with one seizure‐free patient, two patients with a reduction of seizures of more than 75%, and four patients with a decrease of more than 50%.”

Source: [Desnous et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10839357/)

<a id="topic-2.2.2.1.2-9"></a>

### Rescue therapy: diazepam nasal spray for seizure clusters

> “Age- and weight-based doses of diazepam nasal spray (5–20 mg) were administered to patients (aged 6–65 years) for seizure clusters.”
> “All caregivers felt diazepam nasal spray was very/extremely easy to use; 63.6% were able to return to normal activities within an hour of administration.”
> “Diazepam nasal spray has safety and effectiveness profiles consistent with the full study population and was easy to use.”

Source: [Tarquinio et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12970060/)

<a id="topic-2.2.2.1.2-10"></a>

### Trofinetide with concomitant antiseizure medication

> “The most frequently used concomitant medications in the trofinetide and placebo groups were antiseizure medication (64.5% and 72.3%, respectively) and drugs for constipation (60.2% and 70.2%)”

Source: [Neul et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10287558/)

> “Patient history of seizures should be taken prior to initiating trofinetide, if possible”
> “the majority will not experience changes in seizures, while the minority may experience improvement or worsening during treatment, depending on the individual patient”

Source: [Prange et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13359341/)

## Related pages
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Terms and abbreviations](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations.md)
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Product information and disease description](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Clinical evidence](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Economic information and modeling report](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: References](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references.md)
